Study wrapper · #1036
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
Rubino D, Wharton S, Knight MG, et al. Postgraduate medicine. 2026.
DOI: 10.1080/00325481.2026.2686467PubMed: 42286992
Editor's note
An evidence-informed clinical guidance article on oral semaglutide for obesity management, drawing on trial data including OASIS 4 and the authors' clinical experience. It is practical and educational in orientation rather than a source of new outcome data, and readers should note it reflects expert guidance alongside trial evidence. The detailed administration requirements for the oral formulation are a useful, concrete takeaway.
Plain-language abstract
This practice-oriented article offers guidance on using oral semaglutide for obesity, noting weight loss comparable to injectable versions and detailing the specific dosing conditions needed for absorption. It emphasizes patient counseling and managing side effects.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026